ChromaDex amends CEO Fried's contract to $650k base, grants 1.5M PSUs with $15-$50 stock price targets

Niagen Bioscience, Inc.

Base salary increased to $650,000 effective Jan 1, 2025; target bonus raised to 75% of base for FY2025.
CEO granted 1,518,600 PSUs with 7-year performance period; vest at stock price thresholds of $15, $20, $30, $40, $50.
First tranche (759,300 PSUs) vests at $15 VWAP for 60 trading days; subsequent 189,825 each at higher thresholds.
PSUs subject to five-year transfer restriction after vesting; no cash-out feature; forfeiture if targets not met by 2032.
Under termination without cause or for good reason, unvested PSUs remain eligible for 12 months; transfer restrictions lapse.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.